View in EDS

Correction to: Vildagliptin Attenuates Huntington's Disease Through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model.

Saved in:
Bibliographic Details
Title: Correction to: Vildagliptin Attenuates Huntington's Disease Through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model.
Authors: Sayed NH; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt., Fathy N; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt. nevine.abdallah@pharma.cu.edu.eg., Kortam MA; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt., Rabie MA; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt., Mohamed AF; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt., Kamel AS; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt.
Source: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics [Neurotherapeutics] 2022 Mar; Vol. 19 (2), pp. 686.
Publication Type: Published Erratum
Journal Info: Publisher: Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics Country of Publication: United States NLM ID: 101290381 Publication Model: Print Cited Medium: Internet ISSN: 1878-7479 (Electronic) Linking ISSN: 18787479 NLM ISO Abbreviation: Neurotherapeutics Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35352287
AccessLevel: 2
PubTypeId: unknown
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Correction to: Vildagliptin Attenuates Huntington's Disease Through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Sayed+NH%22">Sayed NH</searchLink>; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt.<br /><searchLink fieldCode="AU" term="%22Fathy+N%22">Fathy N</searchLink>; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt. nevine.abdallah@pharma.cu.edu.eg.<br /><searchLink fieldCode="AU" term="%22Kortam+MA%22">Kortam MA</searchLink>; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt.<br /><searchLink fieldCode="AU" term="%22Rabie+MA%22">Rabie MA</searchLink>; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt.<br /><searchLink fieldCode="AU" term="%22Mohamed+AF%22">Mohamed AF</searchLink>; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt.<br /><searchLink fieldCode="AU" term="%22Kamel+AS%22">Kamel AS</searchLink>; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101290381%22">Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</searchLink> [Neurotherapeutics] 2022 Mar; Vol. 19 (2), pp. 686.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Published Erratum
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Inc%2E+on+behalf+of+American+Society+for+Experimental+NeuroTherapeutics%22">Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101290381 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1878-7479 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2218787479%22">18787479 </searchLink><i>NLM ISO Abbreviation: </i>Neurotherapeutics <i>Subsets: </i>MEDLINE; PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35352287
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s13311-022-01227-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 686
    Titles:
      – TitleFull: Correction to: Vildagliptin Attenuates Huntington's Disease Through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sayed NH
      – PersonEntity:
          Name:
            NameFull: Fathy N
      – PersonEntity:
          Name:
            NameFull: Kortam MA
      – PersonEntity:
          Name:
            NameFull: Rabie MA
      – PersonEntity:
          Name:
            NameFull: Mohamed AF
      – PersonEntity:
          Name:
            NameFull: Kamel AS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2022 Mar
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1878-7479
          Numbering:
            – Type: volume
              Value: 19
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
              Type: main
ResultId 1